Cellular vehicles for cancer gene therapy: Current status and future potential

BioDrugs

Volumn 18, Issue 6, 2004, Pages 361-385

  Pereboeva, Larisa ^a   Curiel, David T ^a  

^a and Clinical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CARCINOEMBRYONIC ANTIGEN; CYTOKINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 24; INTERLEUKIN 3; INTERLEUKIN 4; PROTEIN BAX; THROMBOSPONDIN 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CELL BASED GENE THERAPY; ENDOTHELIUM CELL; FIBROBLAST; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; LYMPHOCYTE; LYMPHOCYTE HOMING; MACROPHAGE; MESENCHYME CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW; STEM CELL; SUICIDE GENE; SYSTEMATIC REVIEW; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; CELLS; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; VEHICLES; VIRUSES;

EID: 11144316089     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200418060-00003     Document Type: Review

References (226)

1. Vile RG, Russell SJ, Lemoine NR. Cancer gene therapy: hard lessons and new courses. Gene Ther 2000; 7 (1): 2-8
2. Douglas JT. Cancer gene therapy. Technol Cancer Res Treat 2003; 2 (1): 51-64
3. Pfeifer A, Verma IM. Gene therapy: promises and problems. Annu Rev Genomics Hum Genet 2001; 2: 177-211
4. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4 (5): 346-58
5. Bordignon C, Carlo-Stella C, Colombo MP, et al. Cell therapy: achievements and perspectives. Haematologica 1999; 84(12): 1110-49
6. Halfpenny C, Benn T, Scolding N. Cell transplantation, myelin repair, and multiple sclerosis. Lancet Neurol 2002; 1 (1): 31-40
7. Di Campli C, Nestola M, Piscaglia AC, et al. Cell-based therapy for liver diseases. Eur Rev Med Pharmacol Sci 2003; 7 (2): 41-4
8. Reffelmann T, Leor J, Muller-Ehmsen J, et al. Cardiomyocyte transplantation into the failing heart: new therapeutic approach for heart failure? Heart Fail Rev 2003; 8 (3): 201-11
9. Titus T, Badet L, Gray DW. Islet cell transplantation for insulin-dependant diabetes mellitus: perspectives from the present and prospects for the future. Expert Rev Mol Med 2000; 2000: 1-28
10. Bank A. Human somatic cell gene therapy. Bioessays 1996; 18 (12): 999-1007
11. Bowie KM, Chang PL. Development of engineered cells for implantation in gene therapy. Adv Drug Deliv Rev 1998; 33 (1-2): 31-43
12. Tresco PA, Biran R, Noble MD. Cellular transplants as sources for therapeutic agents. Adv Drug Deliv Rev 2000; 42 (1-2): 3-27
13. Yao SN, Smith KJ, Kurachi K. Primary myoblast-mediated gene transfer: persistent expression of human factor IX in mice. Gene Ther 1994; 1 (2): 99-107
14. Cherington V, Chiang GG, McGrath CA, et al. Retroviral vector-modified bone marrow stromal cells secrete biologically active factor IX in vitro and transiently deliver therapeutic levels of human factor IX to the plasma of dogs after reinfusion. Hum Gene Ther 1998; 9 (10): 1397-407
15. Hurwitz DR, Kirchgesser M, Merrill W, et al. Systemic delivery of human growth hormone or human factor IX in dogs by reintroduced genetically modified autologous bone marrow stromal cells. Hum Gene Ther 1997; 8 (2): 137-56
16. Josephs SF, Loudovaris T, Dixit A, et al. In vivo delivery of recombinant human growth hormone from genetically engineered human fibroblasts implanted within Baxter immunoisolation devices. J Mol Med 1999; 77 (1): 211-4
17. Murphy JE, Rheinwald JG. Intraperitoneal injection of genetically modified, human mesothelial cells for systemic gene therapy. Hum Gene Ther 1997; 8 (16): 1867-79
18. Descamps V, Blumenfeld N, Perricaudet M, et al. Organoids direct systemic expression of erythropoietin in mice. Gene Ther 1995; 2 (6): 411-7
19. Eliopoulos N, Al-Khaldi A, Crosato M, et al. A neovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged in vivo systemic delivery of erythropoietin in nonmyeloablated, immunocompetent mice. Gene Ther 2003; 10 (6): 478-89
20. Naffakh N, Henri A, Villeval JL, et al. Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts. Proc Natl Acad Sci U S A 1995; 92 (8): 3194-8
21. Aebischer P, Pochon NA, Heyd B, et al. Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF. Hum Gene Ther 1996; 7 (7): 851-60
22. Bachoud-Levi AC, Deglon N, Nguyen JP, et al. Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 2000; 11 (12): 1723-9
23. Ishida A, Yasuzumi F. Approach to ex vivo gene therapy in the treatment of Parkinson's disease. Brain Dev 2000; 22 Suppl. 1: S143-7
24. Fitoussi N, Sotnik-Barkai I, Tornatore C, et al. Dopamine turnover and metabolism in the striatum of parkinsonian rats grafted with genetically-modified human astrocytes. Neuroscience 1998; 85 (2): 405-13
25. Blesch A, Tuszynski MH. Cellular GDNF delivery promotes growth of motor and dorsal column sensory axons after partial and complete spinal cord transections and induces remyelination. J Comp Neurol 2003; 467 (3): 403-17
26. Gelse K, Jiang QJ, Aigner T, et al. Fibroblast-mediated delivery of growth factor complementary DNA into mouse joints induces chondrogenesis but avoids the disadvantages of direct viral gene transfer. Arthritis Rheum 2001; 44 (8): 1943-53
27. Murray M, Kim D, Liu Y, et al. Transplantation of genetically modified cells contributes to repair and recovery from spinal injury. Brain Res Brain Res Rev 2002; 40 (1-3): 292-300
28. Leng J, Zhang L, Yao H, et al. Antitumor effects of interleukin-18 gene-modified hepatocyte cell line on implanted liver carcinoma. Chin Med J (Engl) 2003; 116 (10): 1475-9
29. Kremer EJ, Di Falco ND, Opolon P, et al. Adenovirus vector-transduced hepatocytes implanted via a preformed collagen/PTFE support persist for at least 4 weeks in vivo. Gene Ther 1996; 3 (10): 932-6
30. Nagy JA, Shockley TR, Masse EM, et al. Systemic delivery of a recombinant protein by genetically modified mesothelial cells reseeded on the parietal peritoneal surface. Gene Ther 1995; 2 (6): 402-10
31. Mohajeri MH, Figlewicz DA, Bohn MC. Intramuscular grafts of myoblasts genetically modified to secrete glial cell line-derived neurotrophic factor prevent motoneuron loss and disease progression in a mouse model of familial amyotrophic lateral sclerosis. Hum Gene Ther 1999; 10 (11): 1853-66
32. Ozawa CR, Springer ML, Blau HM. A novel means of drug delivery: myoblastmediated gene therapy and regulatable retro viral vectors. Annu Rev Pharmacol Toxicol 2000; 40: 295-317
33. von Degenfeld G, Banfi A, Springer ML, et al. Myoblast-mediated gene transfer for therapeutic angiogenesis and arteriogenesis. Br J Pharmacol 2003; 140 (4): 620-6
34. Taylor R. Cell vehicles for gene transfer to the brain. Neuromuscul Disord 1997; 7 (5): 343-51
35. Ojeifo JO, Forough R, Paik S, et al. Angiogenesis-directed implantation of genetically modified endothelial cells in mice. Cancer Res 1995; 55 (11): 2240-4
36. Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002; 9 (24): 1647-52
37. Vile RG, Tuszynski A, Castleden S. Retroviral vectors: from laboratory tools to molecular medicine. Mol Biotechnol 1996; 5 (2): 139-58
38. McTaggart S, Al-Rubeai M. Retroviral vectors for human gene delivery. Biotechnol Adv 2002; 20 (1): 1-31
39. Naldini L, Verma IM. Lemiviral vectors. Adv Virus Res 2000; 55: 599-609
40. Parks RJ. Improvements in adenoviral vector technology: overcoming barriers for gene therapy. Clin Genet 2000; 58 (1): 1-11
41. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7 (1): 33-40
42. Kootstra NA, Verma IM. Gene therapy with viral vectors. Annu Rev Pharmacol Toxicol 2003; 43: 413-39
43. Rochlitz CF, Jantscheff P, Bongartz G, et al. Gene therapy with cytokine-transfected xenogeneic cells in metastatic tumors. Adv Exp Med Biol 1998; 451: 531-7
44. Tamura M, Shimizu K, Yamada M, et al. Targeted killing of migrating glioma cells by injection of HTK-modified glioma cells. Hum Gene Ther 1997; 8 (4): 381-91
45. Tang Y, Shah K, Messerli SM, et al. In vivo tracking of neural progenitor cell migration to glioblastomas. Hum Gene Ther 2003; 14 (13): 1247-54
46. Barresi V, Belluardo N, Sipione S, et al. Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy. Cancer Gene Ther 2003; 10 (5): 396-402
47. Benedetti S, Pirola B, Pollo B, et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 2000; 6 (4): 447-50
48. Brown AB, Yang W, Schmidt NO, et al. Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum Gene Ther 2003; 14 (18): 1777-85
49. Davidoff AM, Leary MA, Ng CY, et al. Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo. J Pediatr Surg 2001; 36 (1): 30-6
50. Ehtesham M, Kabos P, Kabosova A, et al. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 2002; 62 (20): 5657-63
51. Yang W, Arii S, Mori A, et al. sFlt-1 gene-transfected fibroblasts: a wound-specific gene therapy inhibits local cancer recurrence. Cancer Res 2001; 61 (21): 7840-5
52. Ehtesham M, Kabos P, Gutierrez MA, et al. Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2002; 62 (24): 7170-4
53. Marini III FC, Yu Q, Wickham T, et al. Adenovirus as a gene therapy vector for hematopoietic cells. Cancer Gene Ther 2000; 7 (6): 816-25
54. Conget PA, Minguell JJ. Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells. Exp Hematol 2000; 28 (4): 382-90
55. Shayakhmerov DM, Papayannopoulou T, Stamatoyannopoulos G, et al. Efficient gene transfer into human CD34 (+) cells by a retargeted adenovirus vector. J Virol 2000; 74 (6): 2567-83
56. Pereboeva L, Komarova S, Mikheeva G, et al. Approaches to utilize mesenchymal progenitor cells as cellular vehicles. Stem Cells 2003; 21 (4): 389-404
57. Wysocki PJ, Grabarczyk P, Mackiewiez-Wysocka M, et al. Genetically modified dendritic cells: a new, promising cancer treatment strategy? Expert Opin Biol Ther 2002; 2 (8): 835-45
58. Marini FC, Shayakhmetov D, Gharwan H, et al. Advances in gene transfer into haematopoietic stem cells by adenoviral vectors. Expert Opin Biol Ther 2002; 2 (8): 847-56
59. Hurez V, Hautton RD, Oliver J, et al. Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction. Immunol Res 2002; 26 (1-3): 131-41
60. Burke B, Sumner S, Maitland N, et al. Macrophages in gene therapy: cellular delivery vehicles and in vivo targets. J Leukoc Biol 2002; 72 (3): 417-28
61. Chen QR, Zhang L, Gasper W, et al. Targeting tumor angiogenesis with gene therapy. Mol Genet Metab 2001; 74 (1-2): 120-7
62. Chada S, Ramesh R, Mhashilkar AM. Cytokine- and chemokine-based gene therapy for cancer. Curr Opin Mol Ther 2003; 5 (5); 463-74
63. Davis CB, Gillies SD. Immunocytokines: amplification of anti-cancer immunity. Cancer Immunol Immunother 2003; 52 (5): 297-308
64. Jager E, Jager D, Knuth A. Clinical cancer vaccine trials. Curr Opin Immunol 2002; 14 (2): 178-82
65. Kowalczyk DW, Wysocki PJ, Mackiewicz A. Cancer immunotherapy using cells modified with cytokine genes. Acta Biochim Pol 2003; 50 (3): 613-24
66. Dutcher JP. Therapeutic strategies for cytokines. Curr Opin Oncol 1995; 7 (6): 566-71
67. Sanches R, D'Incan C, Kuiper M, et al. Autologous fibroblasts as potential vehicle for regional ovarian cancer gene therapy. Adv Exp Med Biol 1998; 451: 331-4
68. Tahara H, Lotze MT, Robbins PD, et al. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther 1995; 6 (12): 1607-24
69. Makar TK, Wilt S, Dong Z, et al. IFN-beta gene transfer into the central nervous system using bone marrow cells as a delivery system. J Interferon Cytokine Res 2002; 22 (7): 783-91
70. Studeny M, Marini FC, Champlin RE, et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002; 62 (13): 3603-8
71. Satoh T, Saika T, Ebara S, et al. Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. Cancer Res 2003; 63 (22): 7853-60
72. Miller PW, Sharma S, Stolina M, et al. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther 2000; 11 (1): 53-65
73. Satoh Y, Esche C, Gambotto A, et al. Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol 2002; 2 (6): 337-49
74. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002; 20 (18): 3906-27
75. Feldman AL, Libutti SK. Progress in antiangiogenic gene therapy of cancer. Cancer 2000; 89(6): 1181-94
76. Folkman J. Antiangiogenic gene therapy. Proc Natl Acad Sci U S A 1998; 95 (16): 9064-6
77. Feldman AL, Restifo NP, Alexander HR, et al. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res 2000; 60 (6): 1503-6
78. Read TA, Sorensen DR, Mahesparan R, et al. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotechnol 2001; 19 (1): 29-34
79. Joki T, Machluf M, Atala A, et al. Continuous release of endostatin from microen-capsulated engineered cells for tumor therapy. Nat Biotechnol 2001; 19 (1): 35-9
80. Streit M, Stephen AE, Hawighorst T, et al. Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy. Cancer Res 2002; 62 (7): 2004-12
81. Cirone P, Bourgeois JM, Chang PL. Antiangiogenic cancer therapy with microencapsulated cells. Hum Gene Ther 2003; 14 (11): 1065-77
82. Bergers G, Hanahan D. Cell factories for fighting cancer. Nat Biotechnol 2001; 19 (1): 20-1
83. Niculescu-Duvaz I, Cooper RG, Stribbling SM, et al. Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr Opin Mol Ther 1999; 1 (4): 480-6
84. Filiat C, Carrio M, Cascante A, et al. Suicide gene therapy mediated by the herpes simplex virus thymidine kinase gene/ganciclovir system: fifteen years of application. Curr Gene Ther 2003; 3 (1): 13-26
85. Elion GB. The chemotherapeutic exploitation of virus-specified enzymes. Adv Enzyme Regul 1980; 18: 53-66
86. Kirn D, Niculescu-Duvaz I, Hallden G, et al. The emerging fields of suicide gene therapy and virotherapy. Trends Mol Med 2002; 8 (4 Suppl): S68-73
87. Diaz RM, Bateman A, Emiliusen L, et al. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Ther 2000; 7 (19): 1656-63
88. Bateman AR, Harrington KJ, Kottke T, et al. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res 2002; 62 (22): 6566-78
89. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53 (21): 5274-83
90. Culver KW, Ram Z, Wallbridge S, et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256 (5063): 1550-2
91. Takamiya Y, Short MP, Moolten FL, et al. An experimental model of retrovirus gene therapy for malignant brain tumors. J Neurosurg 1993; 79 (1): 104-10
92. Caruso M, Panis Y, Gagandeep S, et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993; 90 (15): 7024-8
93. Culver KW, Van Gilder J, Link CJ, et al. Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum Gene Ther 1994; 5 (3): 343-79
94. Klatzmann D, Cherin P, Bensimon G, et al. A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma: Study Group on Gene Therapy of Metastatic Melanoma. Hum Gene Ther 1998; 9 (17): 2585-94
95. Ram Z, Culver KW, Oshiro EM, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997; 3 (12): 1354-61
96. Schwarzenberger P, Harrison L, Weinacker A, et al. The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study. Hum Gene Ther 1998; 9 (17): 2641-9
97. Freeman SM, McCune C, Robinson W, et al. The treatment of ovarian cancer with a gene modified cancer vaccine: a phase I study. Hum Gene Ther 1995; 6 (7): 927-39
98. Coukos G, Makrigiannakis A, Kang EH, et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 1999; 5 (6): 1523-37
99. Rancourt C, Robertson III MW, Wang M, et al. Endothelial cell vehicles for delivery of cytotoxic genes as a gene therapy approach for carcinoma of the ovary. Clin Cancer Res 1998; 4 (2): 265-70
100. Rancourt C, Bergeron C, Lane D, et al. Delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for the treatment of ovarian cancer. Cytotherapy 2003; 5 (6): 509-22
101. Kirn D. Virotherapy for cancer: current status, hurdles, and future directions. Cancer Gene Ther 2002; 9 (12): 959-60
102. Vile R, Ando D, Kirn D. The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider. Cancer Gene Ther 2002; 9 (12): 1062-7
103. Kruyt FA, Curiel DT. Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther 2002; 13 (4): 485-95
104. Herrlinger U, Woiciechowski C, Sena-Esteves M, et al. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Mol Ther 2000; 1 (4): 347-57
105. Chester J, Ruchatz A, Gough M, et al. Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nat Biotechnol 2002; 20 (3): 256-63
106. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001; 46 (1-3): 149-68
107. Gao J, Dennis JE, Muzic RF, et al. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001; 169 (1): 12-20
108. Campbell AI, Kuliszewski MA, Stewart DJ. Cell-based gene transfer to the pulmonary vasculature: endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension. Am J Respir Cell Mol Biol 1999; 21 (5): 567-75
109. Devine SM, Bartholomew AM, Mahmud N, et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001; 29 (2): 244-55
110. Sanches R, Kuiper M, Penault-Llorca F, et al. Antitumoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer: implications for the use of ovarian cancer biopsy-derived fibroblasts as a vehicle for regional gene therapy. Cancer Gene Ther 2000; 7 (5): 707-20
111. Roni V, Habeler W, Parenti A, et al. Recruitment of human umbilical vein endothelial cells and human primary fibroblasts into experimental tumors growing in SCID mice. Exp Cell Res 2003; 287 (1): 28-38
112. Kramm CM, Sena-Esteves M, Barnett FH, et al. Gene therapy for brain tumors. Brain Pathol 1995; 5 (4): 345-81
113. Nam M, Johnston P, Lal B, et al. Endothelial cell-based cytokine gene delivery inhibits 9L glioma growth in vivo. Brain Res 1996; 731 (1-2): 161-70
114. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A 2000; 97 (23): 12846-51
115. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003; 3 (1): 35-45
116. Willemsen RA, Debets R, Chames P, et al. Genetic engineering of T cell specificity for immunotherapy of cancer. Hum Immunol 2003; 64 (1): 56-68
117. Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B- lineage leukemia effect. Blood 2003; 101 (4): 1637-44
118. Hombach A, Heuser C, Sircar R, et al. T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. Gastroenterology 1997; 113 (4): 1163-70
119. Hombach A, Koch D, Sircar R, et al. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Ther 1999; 6 (2): 300-4
120. Hombach A, Muche JM, Gerken M, et al. T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30 (+) cutaneous lymphoma cells. Gene Ther 2001; 8 (11): 891-5
121. Jensen MC. Targeting malignant B cells of lymphoma and leukemia with genetically engineered T-cell clones. Cytotherapy 2002; 4 (5): 443-4
122. Jensen MC, Cooper LJ, Wu AM, et al. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy 2003; 5 (2): 131-8
123. Pinthus JH, Waks T, Kaufman-Francis K, et al. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res 2003; 63 (10): 2470-6
124. Kershaw MH, Wang G, Westwood JA, et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther 2002; 13 (16): 1971-80
125. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3 (9): 666-75
126. Knutson KL, Almand B, Mankoff DA, et al. Adoptive T-cell therapy for the treatment of solid tumours. Expert Opin Biol Ther 2002; 2 (1): 55-66
127. Paul S, Calmels B, Acres RB. Improvement of adoptive cellular immunotherapy of human cancer using ex-vivo gene transfer. Curr Gene Ther 2002; 2 (1): 91-100
128. Oldfield EH, Ram Z, Culver KW, et al. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 1993; 4 (1): 39-69
129. Ram Z, Culver KW, Walbridge S, et al. Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. J Neurosurg 1993; 79 (3): 400-7
130. Namba H, Tagawa M, Iwadate Y, et al. Bystander effect-mediated therapy of experimental brain tumor by genetically engineered tumor cells. Hum Gene Ther 1998; 9 (1): 5-11
131. Schwarzenberger P, Lei D, Freeman SM, et al. Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma. Am J Respir Cell Mol Biol 1998; 19 (2): 333-7
132. Ribeiro Jr U, Whiteside TL, Basse PH, et al. Activated natural killer cell tumor retention and cytokine production in colon tumor using a tissue-isolated model. J Surg Res 1999; 82 (1): 78-87
133. Rosenberg SA. Adoptive immunotherapy of cancer: accomplishments and prospects. Cancer Treat Rep 1984; 68 (1): 233-55
134. Ioannides CG, Whiteside TL. T cell recognition of human tumors: implications for molecular immunotherapy of cancer. Clin Immunol Immunopathol 1993; 66 (2): 91-106
135. Stewart JA, Belinson JL, Moore AL, et al. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res 1990; 50 (19): 6302-10
136. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316 (15): 889-97
137. Melief CJ. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992; 58: 143-75
138. Kjaergaard J, Shu S. Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression. J Immunol 1999; 163 (2): 751-9
139. Chang AE, Li Q, Bishop DK, et al. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 2000; 11 (6): 839-50
140. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 183 (3): 725-9
141. Yee C, Riddell SR, Greenberg PD. In vivo tracking of tumor-specific T cells. Curr Opin Immunol 2001; 13 (2): 141-6
142. Moritz D, Wels W, Mattern J, et al. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 1994; 91 (10): 4318-22
143. Kershaw MH, Westwood JA, Zhu Z, et al. Generation of gene-modified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature. Hum Gene Ther 2000; 11 (18): 2445-52
144. Niederman TM, Ghogawala Z, Carter BS, et al. Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors. Proc Natl Acad Sci U S A 2002; 99 (10): 7009-14
145. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298 (5594): 850-4
146. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002; 99 (25): 16168-73
147. Kjaergaard J, Hokland ME, Agger R, et al. Biodistribution and tumor localization of lymphokine-activated killer T cells following different routes of administration into tumor-bearing animals. Cancer Immunol Immunother 2000; 48 (10): 550-60
148. Ribeiro Jr U, Basse PH, Rosenstein M, et al. Retention of adoptively transferred interleukin-2-activated natural killer cells in tumor tissue. Anticancer Res 1997; 17 (2A): 1115-23
149. Yang Q, Hokland ME, Bryant JL, et al. Tumor-localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases. Int J Cancer 2003; 105 (4): 512-9
150. Goldfarb RH, Koelemij R, Muirhead KA, et al. A novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicin. In Vivo 2000; 14 (1): 101-4
151. Basse P, Herberman RB, Nannmark U, et al. Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exp Med 1991: 174 (2): 479-88
152. Crittenden M, Gough M, Chester J, et al. Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy. Cancer Res 2003; 63 (12): 3173-80
153. Chen SY, Yang AG, Chen JD, et al. Potent antitumour activity of a new class of tumour-specific killer cells. Nature 1997; 385 (6611): 78-80
154. Vallera DA, Jin N, Baldrica JM, et al. Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin gene. Cancer Res 2000; 60 (4): 976-84
155. Jin N, Chen W, Blazar BR, et al. Gene therapy of murine solid tumors with T cells transduced with a retroviral vascular endothelial growth factor: immunotoxin target gene. Hum Gene Ther 2002; 13 (4): 497-508
156. Vallera DA, Jin N, Shu Y, et al. Retroviral immunotoxin gene therapy of leukemia in mice using leukemia-specific T cells transduced with an interleukin-3/Bax fusion protein gene. Hum Gene Ther 2003; 14 (18): 1787-98
157. Oberling F. Monocyte/macrophages as effector cells in cancer immunotherapy. Transfus Sci 1997; 18 (2): 243-50
158. Dipietro LA, Reintjes MG, Low QE, et al. Modulation of macrophage recruitment into wounds by monocyte chemoattractant protein-1. Wound Repair Regen 2001; 9 (1): 28-33
159. Ross JA, Auger MJ. The biology of the macrophage. In: Lewis C, editor. The macrophage. Oxford: Oxford University Press, 2002: 676
160. van Reyk DM, Jessup W. The macrophage in atherosclerosis: modulation of cell function by sterols. J Leukoc Biol 1999; 66 (4): 557-61
161. Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol 1999; 26 (3): 717-9
162. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 1998; 64 (3): 275-90
163. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196 (3): 254-65
164. Andreesen R, Scheibenbogen C, Brugger W, et al. A new approach to adoptive immunotherapy of cancer using tumorcytotoxic macrophages grown from peripheral blood monocytes. Cancer Detect Prev 1991; 15 (5): 413-21
165. Normann SJ. Macrophage infiltration and tumor progression. Cancer Metastasis Rev 1985; 4 (4): 277-91
166. Leek RD, Hunt NC, Landers RJ, et al. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol 2000; 190 (4): 430-6
167. Leek RD, Harris AL. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 2002; 7 (2): 177-89
168. Zhang F, Lu W, Dong Z. Tumor-infiltrating macrophages are involved in suppressing growth and metastasis of human prostate cancer cells by INF-beta gene therapy in nude mice. Clin Cancer Res 2002; 8 (9): 2942-51
169. Harris AL. Hypoxia: a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2 (1): 38-47
170. Lewis JS, Lee JA, Underwood JC, et al. Macrophage responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol 1999; 66 (6): 889-900
171. Griffiths L, Binley K, Iqball S, et al. The macrophage: a novel system to deliver gene therapy to pathological hypoxia. Gene Ther 2000; 7 (3): 255-62
172. Audran R, Collet B, Moisan A, et al. Fate of mouse macrophages radiolabelled with PKH-95 and injected intravenously. Nucl Med Biol 1995; 22 (6): 817-21
173. Chokri M, Girard A, Borrelly MC, et al. Adoptive immunotherapy with bispecific antibodies: targeting through macrophages. Res Immunol 1992; 143 (1): 95-9
174. Paul S, Bizouarne N, Dott K, et al. Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody. Cancer Gene Ther 2000; 7 (4): 615-23
175. Shih SC, Claffey KP. Hypoxia-mediated regulation of gene expression in mammalian cells. Int J Exp Pathol 1998; 79 (6): 347-57
176. Carta L, Pastorino S, Melillo G, et al. Engineering of macrophages to produce IFN-gamma in response to hypoxia. J Immunol 2001; 166 (9): 5374-80
177. Binley K, Iqball S, Kingsman A, et al. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer. Gene Ther 1999; 6 (10): 1721-7
178. Pastorino S, Massazza S, Cilli M, et al. Generation of high-titer retroviral vector-producing macrophages as vehicles for in vivo gene transfer. Gene Ther 2001; 8 (6): 431-41
179. Veelken H, Jesuiter H, Mackensen A, et al. Primary fibroblasts from human adults as target cells for ex vivo transfection and gene therapy. Hum Gene Ther 1994; 5 (10): 1203-10
180. Kang WK, Park C, Yoon HL, et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther 2001; 12 (6): 671-84
181. Iwazawa T, Chau GY, Mon T, et al. Potent antitumor effects of intra-arterial injection of fibroblasts genetically engineered to express IL-12 in liver metastasis model of rat: no additional benefit of using retroviral producer cell. Cancer Gene Ther 2001; 8 (1): 17-22
182. Shawler DL, Dorigo O, Gjerset RA, et al. Comparison of gene therapy with interleukin-2 gene modified fibroblasts and tumor cells in the murine CT-26 model of colorectal carcinoma. J Immunother Emphasis Tumor Immunol 1995; 17 (4): 201-8
183. Zitvogel L, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J Immunol 1995; 155 (3): 1393-403
184. Glick RP, Lichtor T, de Zoeten E, et al. Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2. Neurosurgery 1999; 45 (4): 867-74
185. Quintin-Colonna F, Devauchelle P, Fradelizi D, et al. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2. Gene Ther 1996; 3 (12): 1104-12
186. Tahara H, Zeh III HJ, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994; 54 (1): 182-9
187. Glick RP, Lichtor T, Panchal R, et al. Treatment with allogeneic interleukin-2 secreting fibroblasts protects against the development of malignant brain tumors. J Neurooncol 2003; 64 (1-2): 139-46
188. Lichtor T, Glick RP, Tarlock K, et al. Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors. Cancer Gene Ther 2002; 9 (5): 464-9
189. Lotze MT, Rubin JT, Carty S, et al. Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Hum Gene Ther 1994; 5 (1): 41-55
190. Veelken H, Mackensen A, Lahn M, et al. A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int J Cancer 1997; 70 (3): 269-77
191. Suminami Y, Elder EM, Lotze MT, et al. In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine. J Immunother Emphasis Tumor Immunol 1995; 17 (4): 238-48
192. Sobol RE, Shawler DL, Carson C, et al. Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a phase I study. Clin Cancer Res 1999; 5 (9): 2359-65
193. Ojeifo JO, Lee HR, Rezza P, et al. Endothelial cell-based systemic gene therapy of metastatic melanoma. Cancer Gene Ther 2001; 8 (9): 636-48
194. Stocum DL. Stem cells in regenerative biology and medicine. Wound Repair Regen 2001; 9 (6): 429-42
195. Tuan RS, Boland G, Tuli R. Adult mesenchymal stem cells and cell-based tissue engineering. Arthritis Res Ther 2003; 5 (1): 32-45
196. Bunting KD, Hawley RG. Integrative molecular and developmental biology of adult stem cells. Biol Cell 2003; 95 (9): 563-78
197. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284 (5411): 143-7
198. Caplan AI, Brader SP. Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. Trends Mol Med 2001; 7 (6): 259-64
199. Noort WA, Kruisselbrink AB, in't Anker PS, et al. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34 (+) cells in NOD/SCID mice. Exp Hematol 2002; 30 (8): 870-8
200. Minguell JJ, Erices A, Conget P. Mesenchymal stem cells. Exp Biol Med (Maywood) 2001; 226 (6): 507-20
201. Liechty KW, MacKenzie TC, Shaaban AF, et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 2000; 6 (11): 1282-6
202. Chuah MK, Van Damme A, Zwinnen H, et al. Long-term persistence of human bone marrow stromal cells transduced with factor VIH-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice. Hum Gene Ther 2000; 11 (5): 729-38
203. Lee K, Majumdar MK, Buyaner D, et al. Human mesenchymal stem cells maintain transgene expression during expansion and differentiation. Mol Ther 2001; 3 (6): 857-66
204. Barbash IM, Chouraqui P, Baron J, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003; 108 (7): 863-8
205. Shen FH, Visger JM, Balian G, et al. Systemically administered mesenchymal stromal cells transduced with insulin-like growth factor-I localize to a fracture site and potentiate healing. J Orthop Trauma 2002; 16 (9): 651-9
206. Pereira RF, Halford KW, O'Hara MD, et al. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci U S A 1995; 92 (11): 4857-61
207. Okamoto R, Yajima T, Yamazaki M, et al. Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract. Nat Med 2002; 8 (9): 1011-7
208. Hess D, Li L, Martin M, et al. Bone marrow-derived stem cells initiate pancreatic regeneration. Nat Biotechnol 2003; 21 (7): 763-70
209. Hess DC, Hill WD, Martin-Studdard A, et al. Bone marrow as a source of endothelial cells and NeuN-expressing cells after stroke. Stroke 2002; 33 (5): 1362-8
210. Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A 2003; 100 (14): 8407-11
211. Poulsom R, Alison MR, Cook T, et al. Bone marrow stem cells contribute to healing of the kidney. J Am Soc Nephrol 2003; 14 Suppl. 1: S48-54
212. Direkze NC, Forbes SJ, Brittan M, et al. Multiple organ engraftment by bone-marrow-derived myofibroblasts and fibroblasts in bone-marrow-transplanted mice. Stem Cells 2003; 21 (5): 514-20
213. Mahmood A, Lu D, Wang L, et al. Treatment of traumatic brain injury in female rats with intravenous administration of bone marrow stromal cells. Neurosurgery 2001; 49 (5): 1196-203
214. Lu D, Li Y, Wang L, et al. Intraarterial administration of marrow stromal cells in a rat model of traumatic brain injury. J Neurotrauma 2001; 18 (8): 813-9
215. Mackenzie TC, Flake AW. Human mesenchymal stem cells persist, demonstrate site-specific multipotential differentiation, and are present in sites of wound healing and tissue regeneration after transplantation into fetal sheep. Blood Cells Mol Dis 2001; 27 (3): 601-4
216. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276 (5309): 71-4
217. Tepper OM, Sealove BA, Murayama T, et al. Newly emerging concepts in blood vessel growth: recent discovery of endothelial progenitor cells and their function in tissue regeneration. J Investig Med 2003; 51 (6): 353-9
218. Asahara T. Endothelial progenitor cells for neovascularization. Ernst Schering Res Found Workshop 2003; 43: 211-6
219. Murayama T, Asahara T. Bone marrow-derived endothelial progenitor cells for vascular regeneration. Curr Opin Mol Ther 2002; 4 (4): 395-402
220. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003; 9 (6): 702-12
221. Gomez-Navarro J, Contreras JL, Arafat W, et al. Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model. Gene Ther 2000; 7 (1): 43-52
222. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7 (11): 1194-201
223. Davidoff AM, Ng CY, Brown P, et al. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin Cancer Res 2001; 7 (9): 2870-9
224. Ferrari N, Glod J, Lee J, et al. Bone marrow-derived, endothelial progenitor-like cells as angiogenesis-selective gene-targeting vectors. Gene Ther 2003; 10 (8): 647-56
225. Stoll BR, Migliorini C, Kadambi A, et al. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. Blood 2003; 102 (7): 2555-61
226. De Palma M, Venneri MA, Roca C, et al. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 2003; 9 (6): 789-95